Gravelle Hugh, Brouwer Werner, Niessen Louis, Postma Maarten, Rutten Frans
National Primary Care Research and Development Centre (NPCRDC), Centre for Health Economics, University of York, UK.
Health Econ. 2007 Mar;16(3):307-17. doi: 10.1002/hec.1168.
The National Institute for Clinical Excellence has recently changed its guidelines on discounting costs and effects in economic evaluations. In common with most other regulatory bodies it now requires that health effects should be discounted at the same rate as costs. We show that the guideline leads to sub-optimal decisions because it fails to account for the changing value of health. NICE (and other regulatory bodies) should either use differential discounting or stipulate how the changing value of health should otherwise be dealt with. We also show how binding health service budget constraints should be incorporated in evaluations.
英国国家卫生与临床优化研究所(NICE)最近改变了其在经济评估中对成本和效果进行贴现的指导方针。与大多数其他监管机构一样,它现在要求健康效果应以与成本相同的比率进行贴现。我们表明,该指导方针会导致次优决策,因为它没有考虑到健康价值的变化。NICE(以及其他监管机构)要么采用差别贴现,要么规定应如何处理健康价值的变化。我们还展示了应如何将具有约束力的卫生服务预算限制纳入评估之中。